Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 4Completed 4Unknown 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 4997Neoplasms 4192Prostatic Neoplasms 2426Carcinoma, Non-Small-Cell Lung 2261Colorectal Neoplasms 2050Lung Neoplasms 1703Multiple Myeloma 1454Lymphoma 1403Leukemia, Myeloid, Acute 1379Neoplasm Metastasis 1372Melanoma 1269Pancreatic Neoplasms 1200Leukemia 1194Ovarian Neoplasms 1190Lymphoma, Non-Hodgkin 1128Precursor Cell Lymphoblastic Leukemia-Lymphoma 1088Head and Neck Neoplasms 1055Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 896Colonic Neoplasms 893Brain Neoplasms 875Stomach Neoplasms 854Recurrence 848Carcinoma, Hepatocellular 845Glioblastoma 837Lymphoma, Large B-Cell, Diffuse 770Rectal Neoplasms 758Uterine Cervical Neoplasms 725Carcinoma, Renal Cell 704Hodgkin Disease 696

Interventions

Paclitaxel 2Tocotrienols 1Lenalidomide 1EP-100 membrane-disrupting peptide 1Carboplatin 1Bevacizumab 1AC 7700 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × Ovarian Cancer Recurrent × Clear all
NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Vejle Hospital

Phase 2 Completed
20 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01111903 2016-03-17

REV

ARCAGY/ GINECO GROUP

Phase 1/2 Completed
67 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01332656 2015-12-21

OPSALIN

Sanofi

Phase 2 Completed
154 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed
49 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡